Balyasny Asset Management’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-713,026
| Closed | -$36.8M | – | 3562 |
|
|
2022
Q3 | $36.8M | Buy |
+713,026
| New | +$29.5M | 0.11% | 228 |
|
|
2018
Q3 | – | Sell |
-11,125
| Closed | -$147K | – | 2155 |
|
|
2018
Q2 | $147K | Buy |
+11,125
| New | +$133K | ﹤0.01% | 1681 |
|
|
2016
Q2 | – | Sell |
-955,134
| Closed | -$2.38M | – | 1525 |
|
|
2016
Q1 | $2.38M | Sell |
955,134
-676,192
| -41% | -$2.46M | 0.01% | 664 |
|
|
2015
Q4 | $13.2M | Sell |
1,631,326
-699,874
| -30% | -$4.95M | 0.09% | 299 |
|
|
2015
Q3 | $14.1M | Buy |
2,331,200
+85,925
| +4% | +$621K | 0.1% | 264 |
|
|
2015
Q2 | $18.5M | Buy |
2,245,275
+377,678
| +20% | +$3M | 0.11% | 239 |
|
|
2015
Q1 | $14.1M | Buy |
1,867,597
+57,141
| +3% | +$446K | 0.11% | 265 |
|
|
2014
Q4 | $12.4M | Sell |
1,810,456
-953,771
| -35% | -$5.04M | 0.11% | 255 |
|
|
2014
Q3 | $12.4M | Buy |
2,764,227
+10,577
| +0.4% | +$55.9K | 0.1% | 260 |
|
|
2014
Q2 | $16.1M | Buy |
2,753,650
+463,229
| +20% | +$2.6M | 0.18% | 143 |
|
|
2014
Q1 | $15.2M | Buy |
2,290,421
+1,131,808
| +98% | +$7.86M | 0.17% | 151 |
|
|
2013
Q4 | $6.71M | Buy |
1,158,613
+676,213
| +140% | +$3.49M | 0.09% | 269 |
|
|
2013
Q3 | $2.68M | Buy |
+482,400
| New | +$5.22M | 0.04% | 432 |
|
Other funds holding CCXI
Balyasny Asset Management's CCXI Position: Q4 2022 in Review
Balyasny Asset Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 713,026 shares — an estimated $36.8M sold.
Balyasny Asset Management first reported a position in CCXI in Q3 2013 and held it in 13 quarters. The position peaked at $36.8M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Balyasny Asset Management reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Balyasny Asset Management sold 713,026 ChemoCentryx, Inc. shares in Q4 2022, an estimated $36.8M.
- Balyasny Asset Management first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 13 quarters.
- Balyasny Asset Management's ChemoCentryx, Inc. position peaked at $36.8M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.